Evaluation of the performance of the model including age at recruitment, sex and smoking status (red) and a classifier including 24-miRNA panel, age at recruitment, sex and smoking status (blue) assessed using the area under Receiver Operating Characteristics (ROC) curves (AUCs) in the IARC case-control study (2006–2012).

<p>Evaluation of the performance of the model including age at recruitment, sex and smoking status (red) and a classifier including 24-miRNA panel, age at recruitment, sex and smoking status (blue) assessed using the area under Receiver Operating Characteristics (ROC) curves (AUCs) in the IARC case-control study (2006–2012).</p

Select baseline characteristics of the study population (lung cancer cases and controls) recruited in the IARC case-control study (Moscow, Russia, 2006–2012).

<p>^a p value calculated using χ² test for categorical variables and Student’s t-test for continuous variables.</p><p>Select baseline characteristics of the study population (lung cancer cases and controls) recruited in the IARC case-control study (Moscow, Russia, 2006–2012).</p

Logistic regression prediction model with the 24-microRNA panel for patients with lung cancer vs controls in the IARC case-control study (Moscow, Russia, 2006–2012).

<p>^a Model containing the 24-miRNA panel (continuous, normalized Ct values).</p><p>^b Model containing sex (Male, Female), age at interview (continuous), smoking status (Never, Former, Current) and the 24-miRNA panel (continuous, normalized Ct values).</p><p>Abbreviations: OR, odds ratio; CI, confidence interval.</p><p>Logistic regression prediction model with the 24-microRNA panel for patients with lung cancer vs controls in the IARC case-control study (Moscow, Russia, 2006–2012).</p

Evaluation of the performance of the 24-miRNA classifier (left) and a classifier including the 24-miRNA panel, age at recruitment, sex and smoking status (right) assessed using area under Receiver Operating Characteristics (ROC) curves (AUCs) in the IARC case-control study (2006–2012).

<p>Evaluation of the performance of the 24-miRNA classifier (left) and a classifier including the 24-miRNA panel, age at recruitment, sex and smoking status (right) assessed using area under Receiver Operating Characteristics (ROC) curves (AUCs) in the IARC case-control study (2006–2012).</p

Complete list of significant differentially expressed miRNA (p-value < 0.05) in lung cancer patients as compared with controls in the IARC case-control study (Moscow, Russia, 2006–2012)—global miRNA expression profiling using TaqMan Human MicroRNA Array A + B Card Set (v3.0).

<p>^a Limma analysis non-adjusted p-value.</p><p>^b p-value corrected for multiple testing (Benjamini-Holm method).</p><p>FC: fold change (> 1 increased; < 1 decreased expression in lung cancer patients vs. non-cancer controls).</p><p>Complete list of significant differentially expressed miRNA (p-value < 0.05) in lung cancer patients as compared with controls in the IARC case-control study (Moscow, Russia, 2006–2012)—global miRNA expression profiling using TaqMan Human MicroRNA Array A + B Card Set (v3.0).</p

MiRNA detected in plasma samples of 100 patients with lung cancer vs 100 controls on TaqMan microRNA CARD A and CARD B, respectively in the IARC case-control study (2006–2012).

<p>MiRNA detected in plasma samples of 100 patients with lung cancer vs 100 controls on TaqMan microRNA CARD A and CARD B, respectively in the IARC case-control study (2006–2012).</p

Hierarchical cluster analysis of all samples following log-transformation and quantile normalization of the microarray data.

<p>Dendrogram for clustering experiments was created using centred correlation and average linkage method. Length of nodes corresponds to correlation between samples. HCC4_5P: HCC from patient 4 taken at the periphery of the tumor and maintained at room temperature and then frozen in liquid nitrogen at t5 (min).</p

Samples description and microarray quality.

<p>Type of tumor and delay to tumor freezing are shown. RNA integrity is evaluated through the RIN number. The ratio of centiles P95/P05 reflects the overall strength of the signal compared to the background. The Pearson correlation coefficient (r²) shows the correlation between log-expression levels of the central and peripheral samples, for each tumor and each time to cryopreservation.</p><p>HCC: HepatoCellular Carcinoma.</p><p>LC: Lung Carcinoma.</p><p>ND: Not Determined.</p

Within- and between-sample variance box-plot of microarray non-normalized fluorescent signals.

<p>The non-normalized fluorescent signals (AVG_Signal) have been generated by the Illumina Genome Studio V2010.2 for the 3 HepatoCellular Carcinomas (HCC) and the 3 Lung Carcinomas (LC ) samples taken at the center and at the periphery of the tumors and maintained at room temperature and then frozen in liquid nitrogen at different times: 5 minutes (t5, reference time), 15 minutes (t15), 30 minutes (t30) and 120 minutes (t120).</p

Gene expression for all probes and for restricted sets of probes.

<p>Over-all rate of expression changes for all probes in all samples combined, in LC and HCC samples and in peripheral and central samples are estimated as percent-change per hour. Expression levels changes are also estimated for different sets of probes (lowest and highest 5% of geometric mean expression, probes in warm ischemia genes and probes in HCC genes).</p